Home > Authors and editors

Zhan He Wu

Children's Hospital at Westmead Australia

Dr. Zhan He Wu graduated from Harbin Medical University, China, and received his Master’s degree in 1985 from the same university. He received his Ph.D. degree in 1993 from the University of New South Wales, Australia. Since 1996, he has been working in the field of human genetic disease studies in the Sydney Genome Diagnostics, Western Sydney Genetics Program, The Children’s Hospital Westmead, Affiliated to the University of Sydney, mainly on hematological malignancies such as leukemia and lymphoma, and inherited bone marrow failure syndromes, including Fanconi anemia (it is named as the prone cancer syndrome and paradigm for cancer and aging research). Dr. Zhan He Wu has published more than 60 original articles, more than 60 scientific conference presentations, and five chapters in books. He was granted as a Founding Fellow of Royal College of Pathologist for Australasia in 2011. In the past, he has organized many national scientific conferences. He was invited as the Chair for the Euro-Global Conference on Pediatrics and Neonatology 2018, 13–15, SEP, ROME, and delivered the welcome message as well. He has been involved in medical journal reviewing and editing and invited by nine international journals as a reviewer, associate editor, guest editor, editor, column chair, and so on. Currently, he is editing two professional books in English for a UK publisher: Germline Mutations Associated Leukemia and Rare Diseases.

2books edited

4chapters authored

Latest work with IntechOpen by Zhan He Wu

Rare diseases are a group of genetic disorders occurring in a small percentage of the population with the conditions being chronic but incurable. Approximately 7000 to 8000 different types have been identified and about 350 million people globally are affected in childhood and adulthood, resulting in enormous physical, mental, and psychological suffering and financial burden. It is imperative for medical scientists, clinicians, communities, and societies to ensure appropriate care is applied to ease the suffering of such patients. The extraordinary and unprecedented hallmark in the field of rare diseases has revolutionized modern human medicine with exciting and advancing developments of the genomic era over the last two decades. Patients with rare diseases have been receiving increasing benefits in care and life quality improvements than ever before. This book intends to share and exchange the advancing knowledge and experiences from the authors, who have the necessary expertise within the various topics and subjects in the research, diagnosis, and management of rare diseases. It is hoped they are able to provide further benefits to patients and families with the development of early and accurate diagnosis and effective therapies.

Rare Diseases

Rare Diseases

Edited by Zhan He Wu

Books edited

Germ Line Mutations Associated Leukemia

Germ Line Mutations Associated Leukemia

Edited by Zhan He Wu

Chapters authored

Inherited Bone Marrow Failure and Chromosome Instability Syndromes and their Cancer Predisposition

By Zhan He Wu

Inherited bone marrow failure syndromes (IBMFS) and chromosome instability syndromes (CIS) are the most classic and representative genetic syndromes. They are classified as genetic rare diseases, typically with complex medical complications in the delay of mental and physical development. Commonly, these syndromes present with different degrees of dysmorphics; organs/systems dysfunction generally and these syndromes have higher risk of inherited solid cancer and leukemia predisposition due to the similar pathway of DNA defects. These syndromes are often hard to diagnose and they overlap with their phenotypes clinically. Very importantly cancers from the germ line mutation of these syndromes require different treatment strategies with the sporadic malignancies. The significance of recognition of such diseases is not only beneficial to patients phenotypically affected but also to individuals phenotypically unaffected and members/relatives of the family. Remarkable advances have been made in the definition and classification of these genetic syndromes. Identification of the IBMFS and CIS has led to important advances in the understanding of the genotypes, guiding the clinical practice of the phenotypes. Interestingly, such studies provided insights into the function of the various DNA repair pathways. Fanconi anemia studies are an example in IBMFS and CIS is named as the paradigm of the studies of cancer and aging.

Part of the book: Contemporary Pediatric Hematology and Oncology

Introductory Chapter: Germline Mutations Associated with Leukaemia - Different Genetic Landscape and Therapeutic Strategies

By Zhan He Wu

Part of the book: Germ Line Mutations Associated Leukemia

Introductory Chapter: Advances in the Diagnosis and Management of Rare Diseases

By Zhan He Wu

Part of the book: Rare Diseases

Milestone Histories and Paradigmatic Genetic Discoveries of Chronic Myeloid Leukemia (CML)

By Zhan He Wu

Chronic myeloid leukemia (CML) is classified as a hematological malignant rare disease by National Organization for Rare Disease (NORD, USA) based on the estimated incidence of 1–2 cases/100,000 per year internationally. CML occurs in all ages but commonly seen in the 45–55 years group. Males are slightly more affected than females. CML is one of the oldest known diseases with new faces and one of the fastest developing diseases with many extraordinary discoveries in human history of conquering the disease. CML possesses at least Nine First findings in leukemia and cancer research and even in human medical histories: the First named as leukemia in 1845, the First of a live case of CML patient diagnosed in 1846, the First used of arsenic in CML treatment in 1865, the First defined as a myeloproliferative disorder in 1951, the First finding of Philadelphia chromosome (Ph chromosome) in 1960, the First finding of chromosome 9 and 22 translocations in 1973, the First identified as a clonal hematological malignancy derived from the stage of pluripotent bone hematopoietic stem cells in 1977, the First finding of the chromosomal fusion gene-BCR-ABL as an oncogene in 1984, and the First designed target therapy of use of tyrosine kinase inhibitor (TKI) in 1998. The footprints of the studies on CML established the milestone histories. Remarkable and fascinating genetic discoveries were made of the mysteries of human diseases, the multiway translocation of Ph chromosome, and the latest issues. The association of the combination of chronic myeloid leukemia and chronic lymphocytic leukemia will be reviewed in this chapter with the aim of increasing the understanding of CML further from laboratory bench to clinical bedside.

Part of the book: Rare Diseases

Related collaborators

Maxim Rykov

Tver State Medical University, Russia

Tamer Hassan

Zagazig University

Marwa Zakaria

Zagazig University

Samuel N. Uwaezuoke

University of Nigeria, Nsukka , Nigeria

Chizoma Eneh

Enugu State University of Science and Technology , Nigeria

Osita Ezenwosu

Arturo Solís Herrera

Centro de Estudios de la Fotosíntesis Humana

Duohui Jing

Children's Cancer Institute Australia , Australia

Bingzhi He

Ikenna K. Ndu